CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

FDA gives green light to myopia management contact lens

The US Food and Drug Administration has approved the use of MiSight to slow the progression of myopia in children aged between eight and 12

close up contact lens
CooperVision’s MiSight contact lens has become the first contact lens to be approved for myopia management by the US Food and Drug Administration (FDA).

The FDA has consented to the use of the contact lens to slow the progression of myopia in children aged between eight and 12 at the beginning of treatment.

The approval of the contact lens follows a three-year randomised, controlled trial involving 135 children between eight and 12 who wore either MiSight or a conventional soft contact lens.

MiSight lenses were shown to reduce the progression of myopia and the rate of growth in axial length, with no serious adverse ocular events recorded among study participants who used the lenses.

The FDA also highlighted research showing that the proportion of vision-threatening corneal infections was similar among children and teenagers who wear soft contact lenses daily when compared to adult daily soft contact lens wearers.